

# Michael S Kostapanos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5990839/publications.pdf>

Version: 2024-02-01

85  
papers

2,809  
citations

270111  
25  
h-index

206121  
51  
g-index

85  
all docs

85  
docs citations

85  
times ranked

4571  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lipoprotein (a) as a treatment target for cardiovascular disease prevention and related therapeutic strategies: a critical overview. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 739-755.	0.8	8
2	Is there a role of lipid-lowering therapies in the management of fatty liver disease?. <i>World Journal of Hepatology</i> , 2022, 14, 119-139.	0.8	13
3	Regulatory T-Cell Response to Low-Dose Interleukin-2 in Ischemic Heart Disease. , 2022, 1, .		12
4	Early Investigational and Experimental Therapeutics for the Treatment of Hypertriglyceridemia. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 42.	0.8	1
5	Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment. <i>World Journal of Diabetes</i> , 2022, 13, 85-96.	1.3	14
6	Comparison of the Pharmacokinetics of RIPK1 Inhibitor GSK2982772 in Healthy Western and Japanese Subjects. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 71-83.	0.6	13
7	Baricitinib set to join the Covid-19 therapeutic arsenal?. <i>Rheumatology</i> , 2021, 60, 1585-1587.	0.9	7
8	Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, parallel group, mechanistic study. <i>BMJ Open</i> , 2021, 11, e037457.	0.8	4
9	Recent developments in pharmacotherapy for hypertriglyceridemia: whatâ€™s the current state of the art?. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 107-120.	0.9	10
10	mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial. <i>Trials</i> , 2020, 21, 690.	0.7	14
11	Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 â€œ Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 626.	0.7	32
12	Investigating the lowest threshold of vascular benefits from LDL cholesterol lowering with a PCSK9 mAb inhibitor (alirocumab) in healthy volunteers â€œ a mechanistic physiological study (INTENSITY-LOW): protocol and study rationale. <i>Journal of Drug Assessment</i> , 2019, 8, 167-174.	1.1	1
13	AB0496â€¦ <sup>18</sup> >F-FDG-PET/CT,<sup>11</sup>C-METHIONINE-PET/CT AND MULTI-PARAMETRIC MRI IN THE EVALUATION OF DISEASE ACTIVITY AND GLAND FUNCTION IN PRIMARY SJÄ–GRENâ€™S SYNDROME. , 2019, , .		0
14	Prevalence, Identification, and Scouting for Familial Hypercholesterolaemia Including Registries. <i>Current Pharmaceutical Design</i> , 2019, 24, 3605-3615.	0.9	5
15	Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects. <i>Antiviral Therapy</i> , 2019, 24, 301-308.	0.6	16
16	Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trial. <i>BMJ Open</i> , 2018, 8, e022452.	0.8	83
17	Statins and mortality: the untold story. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 938-941.	1.1	4
18	Clinical relevance of central blood pressure - a critical review. <i>Vasa - European Journal of Vascular Medicine</i> , 2016, 45, 451-460.	0.6	6

#	ARTICLE	IF	CITATIONS
19	How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic. <i>Current Medical Research and Opinion</i> , 2015, 31, 221-228.	0.9	25
20	Lipid Target Achievement Among Patients With Very High and High Cardiovascular Risk in a Lipid Clinic. <i>Angiology</i> , 2015, 66, 346-353.	0.8	27
21	Effects of benchmarking on the quality of type 2 diabetes care: results of the OPTIMISE (Optimal Type 2) Tj ETQq1 1 0.784314 rgBT /O <i>Advances in Endocrinology and Metabolism</i> , 2015, 6, 199-209.	1.4	3
22	Variable effects of statins on glucose homeostasis parameters and their diabetogenic role. <i>Diabetologia</i> , 2015, 58, 1960-1961.	2.9	8
23	Statins and their increased risk of inducing diabetes. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1835-1844.	1.0	27
24	The Effect of Rosuvastatin on Low-Density Lipoprotein Subfractions in Patients With Impaired Fasting Glucose. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2015, 20, 276-283.	1.0	8
25	Emerging drugs for hyperlipidaemia: an update. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 471-488.	1.0	5
26	Benefitâ€“Risk Assessment of Rosuvastatin in the Treatment of Atherosclerosis and Related Diseases. <i>Drug Safety</i> , 2014, 37, 481-500.	1.4	4
27	Hemostatic Factors and the Metabolic Syndrome. <i>Current Vascular Pharmacology</i> , 2014, 11, 880-905.	0.8	39
28	Rationale, design and baseline patient characteristics of the optimal type 2 diabetes management including benchmarking and standard treatment study in Greece. <i>World Journal of Diabetes</i> , 2014, 5, 76.	1.3	4
29	High density lipoproteins and type 2 diabetes: Emerging concepts in their relationship. <i>World Journal of Experimental Medicine</i> , 2014, 4, 1.	0.9	15
30	Fenofibrate and the kidney: an overview. <i>European Journal of Clinical Investigation</i> , 2013, 43, 522-531.	1.7	46
31	Modelling eating practices in non-fatal acute coronary syndrome or stroke development: A case/case-control study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2013, 23, 242-249.	1.1	8
32	Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity. <i>Journal of Clinical Lipidology</i> , 2013, 7, 88.	0.6	2
33	Gender Differences in the Epidemiology, Clinical Presentation, Prevention, and Prognosis of Acute Coronary Syndromes. <i>Angiology</i> , 2013, 64, 5-8.	0.8	3
34	Effect of Simvastatin/Ezetimibe 10/10 mg Versus Simvastatin 40 mg on Serum Vitamin D Levels. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013, 18, 229-233.	1.0	19
35	Colesevelam Plus Rosuvastatin 5â€“mg/Day Versus Rosuvastatin 10â€“mg/Day Alone on Markers of Insulin Resistance in Patients with Hypercholesterolemia and Impaired Fasting Glucose. <i>Metabolic Syndrome and Related Disorders</i> , 2013, 11, 152-156.	0.5	15
36	Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension. <i>Journal of Human Hypertension</i> , 2013, 27, 44-50.	1.0	18

#	ARTICLE	IF	CITATIONS
37	Editorial (Hot Topic: Achieving Current Goals in Prevention and Treatment of Vascular Disease: An Tj ETQq1 1 0.784314 rgBT <sub>0</sub> /Overlo	0.9	11
38	Mitochondrial Triglyceride Transfer Protein Inhibition: New Achievements in the Treatment of Dyslipidemias. <i>Current Pharmaceutical Design</i> , 2013, 19, 3150-3160.	0.9	11
39	Pioglitazone and Cancer: Angel or Demon?. <i>Current Pharmaceutical Design</i> , 2013, 19, 4913-4929.	0.9	34
40	Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2013, 5, 470.	0.8	124
41	The impact of the metabolic syndrome on health-related quality of life: a cross-sectional study in Greece. <i>European Journal of Cardiovascular Nursing</i> , 2012, 11, 297-303.	0.4	40
42	Adding ezetimibe to statin treatment: is LDL-C lowering the only benefit?. <i>Future Cardiology</i> , 2012, 8, 813-817.	0.5	3
43	Obstructive Sleep Apnea and Cardiovascular Risk. <i>Angiology</i> , 2012, 63, 569-573.	0.8	17
44	Therapeutic options for statin-intolerant patients. <i>Current Medical Research and Opinion</i> , 2012, 28, 345-349.	0.9	5
45	Effect of Atorvastatin Monotherapy and Low-Dose Atorvastatin/Ezetimibe Combination on Fasting and Postprandial Triglycerides in Combined Hyperlipidemia. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2012, 17, 427-427.	1.0	5
46	Hypertriglyceridemia-induced acute pancreatitis: clinical considerations. <i>Clinical Lipidology</i> , 2012, 7, 259-262.	0.4	2
47	Effect of rosuvastatin monotherapy or in combination with fenofibrate or Ï‰-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome. <i>International Journal of Clinical Practice</i> , 2012, 66, 843-853.	0.8	23
48	New-onset extremely low levels of high-density lipoprotein cholesterol. <i>Journal of Clinical Lipidology</i> , 2012, 6, 593-595.	0.6	7
49	Ezetimibe â€“ a new approach in hypercholesterolemia management. <i>Pharmacological Reports</i> , 2012, 64, 997-998.	1.5	5
50	Association Between Omega-3 Fatty Acid Supplementation and Risk of Major Cardiovascular Disease Events. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1024.	3.8	868
51	Editorial [ Reducing Cardiovascular Risk: Is Low-Density Lipoprotein-Cholesterol (LDL-C) Lowering Enough? ]. <i>Current Vascular Pharmacology</i> , 2012, 10, 173-177.	0.8	11
52	Letter to the Editor Obstructive sleep apnoea syndrome and cardiovascular risk. <i>Archives of Medical Science</i> , 2012, 6, 1115-1116.	0.4	18
53	Targeting cardiovascular risk: the impact of age, gender and compliance to treatment. <i>Current Medical Research and Opinion</i> , 2012, 28, 1415-1419.	0.9	5
54	Mechanisms Linking Nonalcoholic Fatty Liver Disease with Coronary Artery Disease. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1109-1109.	1.1	9

#	ARTICLE	IF	CITATIONS
55	Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. <i>International Journal of Clinical Practice</i> , 2011, 65, 1141-1148.	0.8	62
56	Clopidogrel vs. Aspirin Treatment on Admission Improves 5-Year Survival After a First-ever Acute Ischemic Stroke. Data from the Athens Stroke Outcome Project. <i>Archives of Medical Research</i> , 2011, 42, 443-450.	1.5	6
57	Ezetimibe Treatment Lowers Indicators of Oxidative Stress in Hypercholesterolemic Subjects with High Oxidative Stress. <i>Lipids</i> , 2011, 46, 341-348.	0.7	30
58	The association between Type D personality and the metabolic syndrome: a cross-sectional study in a University-based outpatient lipid clinic. <i>BMC Research Notes</i> , 2011, 4, 105.	0.6	22
59	JUPITER and satellites: Clinical implications of the JUPITER study and its secondary analyses. <i>World Journal of Cardiology</i> , 2011, 3, 207.	0.5	9
60	Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: A 24-week, randomized, open-label, prospective study. <i>Clinical Therapeutics</i> , 2010, 32, 492-505.	1.1	43
61	Apolipoprotein B-to-A1 Ratio as a Predictor of Acute Ischemic Nonembolic Stroke in Elderly Subjects. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2010, 19, 497-502.	0.7	22
62	Plasma triglyceride levels and body mass index values are the most important determinants of pre $\beta$ -1 HDL concentrations in patients with various types of primary dyslipidemia. <i>Atherosclerosis</i> , 2010, 208, 506-511.	0.4	16
63	Rosuvastatin-Associated Adverse Effects and Drug-Drug Interactions in the Clinical Setting of Dyslipidemia. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 11-28.	1.0	78
64	Current role of statins in the treatment of essential hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2635-2650.	0.9	14
65	Do Statins Beneficially or Adversely Affect Glucose Homeostasis?. <i>Current Vascular Pharmacology</i> , 2010, 8, 612-631.	0.8	58
66	Dose-dependent Effect of Rosuvastatin Treatment on HDL-subfraction Phenotype in Patients With Primary Hyperlipidemia. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2009, 14, 5-13.	1.0	27
67	Efficacy and Safety of Ezetimibe Plus Orlistat or Rimonabant in Statin-Intolerant Nondiabetic Overweight/Obese Patients With Dyslipidemia. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2009, 14, 274-282.	1.0	9
68	Statin Pleiotropy Against Renal Injury. <i>Journal of the Cardiometabolic Syndrome</i> , 2009, 4, E4-9.	1.7	35
69	Association Between Serum $\gamma$ -Glutamyltransferase and Acute Ischemic Nonembolic Stroke in Elderly Subjects. <i>Archives of Medical Research</i> , 2009, 40, 582-589.	1.5	21
70	Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose. <i>International Journal of Clinical Practice</i> , 2009, 63, 1308-1313.	0.8	50
71	Does intensive cholesterol lowering increase the risk of diabetes?. <i>International Journal of Clinical Practice</i> , 2009, 63, 1809-1809.	0.8	0
72	Hypertriglyceridaemic waist phenotype criteria and prevalent metabolic triad in women. <i>Diabetes/Metabolism Research and Reviews</i> , 2008, 24, 223-230.	1.7	11

#	ARTICLE	IF	CITATIONS
73	The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. <i>Diabetes, Obesity and Metabolism</i> , 2008, 10, 476-483.	2.2	58
74	Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. <i>European Journal of Pharmacology</i> , 2008, 578, 249-252.	1.7	28
75	Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia. <i>European Journal of Pharmacology</i> , 2008, 590, 327-332.	1.7	25
76	Analysis of 6-month effect of orlistat administration, alone or in combination with fenofibrate, on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome. <i>Journal of Clinical Lipidology</i> , 2008, 2, 279-284.	0.6	20
77	An Overview of the Extra-Lipid Effects of Rosuvastatin. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2008, 13, 157-174.	1.0	67
78	Do statins have an antiarrhythmic activity?. <i>Cardiovascular Research</i> , 2007, 75, 10-20.	1.8	63
79	Differential Effect of Hypolipidemic Drugs on Lipoprotein-Associated Phospholipase A <sub>2</sub> . <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 2236-2243.	1.1	118
80	Impact of renin-angiotensin-aldosterone system genes on the treatment response of patients with hypertension and metabolic syndrome. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2007, 8, 181-189.	1.0	23
81	Dose-Dependent Effect of Rosuvastatin Treatment on Urinary Protein Excretion. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2007, 12, 292-297.	1.0	23
82	A 12-Week, Prospective, Open-Label Analysis of the Effect of Rosuvastatin on Triglyceride-Rich Lipoprotein Metabolism in Patients with Primary Dyslipidemia. <i>Clinical Therapeutics</i> , 2007, 29, 1403-1414.	1.1	47
83	Different definitions of the metabolic syndrome and risk of first-ever acute ischaemic non-embolic stroke in elderly subjects. <i>International Journal of Clinical Practice</i> , 2007, 61, 545-551.	0.8	30
84	Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATORvastatin and ROSuvastatin (the ATOROS study). <i>Current Medical Research and Opinion</i> , 2006, 22, 1123-1131.	0.9	63
85	Rosuvastatin Increases $\hat{\pm}$ -1 Microglobulin Urinary Excretion in Patients With Primary Dyslipidemia. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 1337-1343.	1.0	25